Alessandro Santin, MD
Professor
Yale University School of Medicine
OB/GYN & Reproductive Sciences
333 Cedar Street
New Haven,
CT
USA
06520
Papers:
140
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo
182
Cervical adenocarcinoma in situ: an institutional retrospective review of surgical management and outcome
262
Choice of adjuvant chemotherapy following neoadjuvant carboplatin/paclitaxel and delayed primary debulking
356
Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations
401
Mutations in the PIK3 pathway as a major determinant of trastuzumab resistance in uterine serous carcinoma